<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00653588</url>
  </required_header>
  <id_info>
    <org_study_id>4522IL/0106</org_study_id>
    <secondary_id>D3569C00005</secondary_id>
    <nct_id>NCT00653588</nct_id>
  </id_info>
  <brief_title>Polaris - Crestor 40 mg vs Atorvastatin 80 mg for 26 Weeks</brief_title>
  <acronym>POLARIS</acronym>
  <official_title>A 26-Week, Double Blind, Randomised, Multi-Centre, Phase IIIb, Parallel Group Study to Compare the Efficacy and Safety of Rosuvastatin (40 mg) With Atorvastatin (80 mg) in Subjects With Hypercholesterolaemia and Coronary Heart Disease or CHD Risk Equivalents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of 8 weeks of treatment with Rosuvastatin
      with 8 weeks of treatment with Atorvastatin on low density lipoprotein cholesterol level in
      subjects with hypercholesterolemia and coronary heart disease (CHD) or at high risk of CHD..
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the efficacy of rosuvastatin with atorvastatin by assessing the percentage change from baseline to week 8 in LDL-C concentrations in subjects with hypercholesterolaemia and CHD or CHD risk equivalents.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of rosuvastatin with atorvastatin in modifying other lipids and lipoproteins at week 8</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Hypercholesterolemia</condition>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rosuvastatin (40 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>atorvastatin (80 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>40mg</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>80mg</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A history of CHD or clinical evidence of atherosclerosis or multiple risk factors that
             confer a high risk as defined in the protocol.

          -  Fasting LDL-C concentrations at Visit 1 as defined in the protocol.

        Exclusion Criteria:

          -  History of statin induced serious side effects, or serious hypersensitivity reaction
             to other statins.

          -  Subjects considered to be unstable by the investigator after the following events: a
             myocardial infarction (heart attack), unstable angina, myocardial revascularisation or
             another revascularisation procedure or a transient ischaemic attack (TIA) or stroke.

          -  Severe congestive cardiac failure (as defined by the protocol - Appendix I).

          -  Subjects awaiting a planned myocardial revascularisation prior to starting the study
             (i.e. planned prior to visit 1).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Lawrence Leiter</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Michaels hospital, Canada</affiliation>
  </overall_official>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2008</study_first_submitted>
  <study_first_submitted_qc>April 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2008</study_first_posted>
  <last_update_submitted>March 13, 2009</last_update_submitted>
  <last_update_submitted_qc>March 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Elisabeth Bj√∂rk</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Cholesterol</keyword>
  <keyword>low density lipoproteins</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Coronary Heart Disease</keyword>
  <keyword>Rosuvastatin</keyword>
  <keyword>Crestor</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>Lipitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

